Company Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 29/04/2024 BST			5-day change	1st Jan Change
0.675 ^USD	-1.03%		-3.57%	-11.18%

04-22	Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	CI
04-16	Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	CI

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cellsâ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Number of employees: 9

Managers	Title	Age	Since
Robert Bitterman CEO	Chief Executive Officer	73	18/06/12
Caitlin Kontulis DFI	Director of Finance/CFO	-	-
James Cardia CTO	Chief Tech/Sci/R&D Officer	-	14/09/17
Linda M. Mahoney PRN	Corporate Officer/Principal	-	09/11/22

Members of the board	Title	Age	Since
Robert Bitterman CEO	Chief Executive Officer	73	18/06/12
Patricia Bradford BRD	Director/Board Member	73	01/05/22
Curtis Lockshin BRD	Director/Board Member	64	17/04/13
Jonathan Freeman BRD	Director/Board Member	56	06/06/17
Robert Ferrara BRD	Director/Board Member	73	30/09/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,591,700	4,564,638 ( 99.41 %)	0	99.41 %

Name	Equities	%	Valuation
Sabby Management LLC 7.068 %	172,693	7.068 %	117 431 $
Anson Funds Management LP 6.443 %	157,425	6.443 %	107 049 $
Citadel Securities GP LLC 1.303 %	31,843	1.303 %	21 653 $
Vanguard Group, Inc. (Subfiler) 0.9978 %	24,380	0.9978 %	16 578 $
Bridgeway Capital Management LLC 0.9612 %	23,486	0.9612 %	15 970 $
Renaissance Technologies LLC 0.8617 %	21,056	0.8617 %	14 318 $
BMO Bank NA (Investment Management) 0.8185 %	20,000	0.8185 %	13 600 $
Virtu Financial LLC 0.7794 %	19,044	0.7794 %	12 950 $
Cetera Investment Advisers LLC 0.6923 %	16,916	0.6923 %	11 503 $
Cambridge Investment Research, Inc. 0.5825 %	14,233	0.5825 %	9 678 $

Phio Pharmaceuticals Corp.

11 Apex Drive Suite 300A PMB 2006

01752, Marlborough

+508 767 3861

http://www.phiopharma.com

address Phio Pharmaceuticals Corp.(PHIO)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.682 USD

Average target price

4 USD

Spread / Average Target

+486.51%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHIO PHARMACEUTICALS CORP.	-11.18%	3.13M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research